Ratiopharm plots 600 layoffs

Ratiopharm plans to cut 600 jobs over the next 18 months, as it seeks to reduce its annual operating costs by approximately €100 million. The move will affect one in nine of the company's global workforce of 5,400 staff. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.